240 related articles for article (PubMed ID: 2909650)
1. Application of an erythrocyte aluminum assay in the diagnosis of aluminum-associated microcytic anemia in patients undergoing dialysis and response to deferoxamine therapy.
Abreo K; Brown ST; Sella M; Trapp G
J Lab Clin Med; 1989 Jan; 113(1):50-7. PubMed ID: 2909650
[TBL] [Abstract][Full Text] [Related]
2. Improvement of anemia with deferoxamine in hemodialysis patients with aluminum-induced bone disease.
Tielemans C; Collart F; Wens R; Smeyers-Verbeeke J; van Hooff I; Dratwa M; Verbeelen D
Clin Nephrol; 1985 Nov; 24(5):237-41. PubMed ID: 4075595
[TBL] [Abstract][Full Text] [Related]
3. Clinical experience with desferrioxamine in dialysis patients with aluminium toxicity.
McCarthy JT; Milliner DS; Johnson WJ
Q J Med; 1990 Mar; 74(275):257-76. PubMed ID: 2117295
[TBL] [Abstract][Full Text] [Related]
4. Microcytic anemia in dialysis patients: reversible marker of aluminum toxicity.
Swartz R; Dombrouski J; Burnatowska-Hledin M; Mayor G
Am J Kidney Dis; 1987 Mar; 9(3):217-23. PubMed ID: 3826071
[TBL] [Abstract][Full Text] [Related]
5. Serum aluminum levels and erythrocyte dihydropteridine reductase activity in patients on hemodialysis.
Altmann P; Al-Salihi F; Butter K; Cutler P; Blair J; Leeming R; Cunningham J; Marsh F
N Engl J Med; 1987 Jul; 317(2):80-4. PubMed ID: 3587329
[TBL] [Abstract][Full Text] [Related]
6. [The effect of hemodialysis and continuous ambulatory peritoneal dialysis on renal anemia].
Stojimirović B; Grujić-Adanja G
Srp Arh Celok Lek; 1997; 125(5-6):163-7. PubMed ID: 9265238
[TBL] [Abstract][Full Text] [Related]
7. Correction of haemodialysis-associated anaemia by deferoxamine. Effects on serum aluminum and iron overload.
von Bonsdorff M; Sipilä R; Pitkänen E
Scand J Urol Nephrol Suppl; 1990; 131():49-54. PubMed ID: 2075470
[TBL] [Abstract][Full Text] [Related]
8. Effect of continuous ambulatory peritoneal dialysis on anemia in uremic patients.
Marcovici O; Boner G; Rosenfeld JB
Isr J Med Sci; 1983 Jul; 19(7):604-7. PubMed ID: 6885343
[TBL] [Abstract][Full Text] [Related]
9. [Aluminum poisoning in dialysis patients--diagnosis and therapy].
Vogelsang U
Schweiz Rundsch Med Prax; 1994 Jun; 83(24):738-56. PubMed ID: 8023059
[TBL] [Abstract][Full Text] [Related]
10. Low serum aluminum values in dialysis patients with increased bone aluminum levels.
van Landeghem GF; D'Haese PC; Lamberts LV; Djukanovic L; Pejanovic S; Goodman WG; De Broe ME
Clin Nephrol; 1998 Aug; 50(2):69-76. PubMed ID: 9725776
[TBL] [Abstract][Full Text] [Related]
11. [Chronic aluminum poisoning in continuous ambulatory peritoneal dialysis: treatment with deferoxamine].
Passlick J; Wilhelm M; Busch T; Grabensee B; Ohnesorge FK
Dtsch Med Wochenschr; 1989 Feb; 114(7):253-7. PubMed ID: 2917487
[TBL] [Abstract][Full Text] [Related]
12. Correlation between serum aluminum concentration and signs of encephalopathy in a large population of patients dialyzed with aluminum-free fluids.
Rovelli E; Luciani L; Pagani C; Albonico C; Colleoni N; D'Amico G
Clin Nephrol; 1988 Jun; 29(6):294-8. PubMed ID: 3396232
[TBL] [Abstract][Full Text] [Related]
13. The role of aluminum in the pathogenesis of anemia in an outpatient hemodialysis population.
Yuan B; Klein MH; Contiguglia RS; Mishell JL; Seligman PA; Miller NL; Molitoris BA; Alfrey AC; Shapiro JI
Ren Fail; 1989; 11(2-3):91-6. PubMed ID: 2623200
[TBL] [Abstract][Full Text] [Related]
14. Serum ferritin and tissue iron in anemic dialysis patients.
Bárány P; Eriksson LC; Hultcrantz R; Pettersson E; Bergström J
Miner Electrolyte Metab; 1997; 23(3-6):273-6. PubMed ID: 9387132
[TBL] [Abstract][Full Text] [Related]
15. Iron overload, but not treatment with desferrioxamine favours the development of septicemia in patients on maintenance hemodialysis.
Seifert A; von Herrath D; Schaefer K
Q J Med; 1987 Dec; 65(248):1015-24. PubMed ID: 3455553
[TBL] [Abstract][Full Text] [Related]
16. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
Attallah N; Osman-Malik Y; Frinak S; Besarab A
Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of intramuscular and intraperitoneal deferoxamine for aluminum chelation.
Molitoris BA; Alfrey PS; Miller NL; Hasbargen JA; Kaehney WD; Alfrey AC; Smith BJ
Kidney Int; 1987 Apr; 31(4):986-91. PubMed ID: 3586503
[TBL] [Abstract][Full Text] [Related]
18. Encephalopathy in chronic renal failure responsive to deferoxamine therapy. Another manifestation of aluminum neurotoxicity.
Sprague SM; Corwin HL; Wilson RS; Mayor GH; Tanner CM
Arch Intern Med; 1986 Oct; 146(10):2063-4. PubMed ID: 3767553
[TBL] [Abstract][Full Text] [Related]
19. Aluminum and deferoxamine kinetics in CAPD.
Mactier RA
Adv Perit Dial; 1991; 7():26-9. PubMed ID: 1680440
[TBL] [Abstract][Full Text] [Related]
20. Intraperitoneal deferoxamine therapy for aluminum intoxication in a child undergoing continuous ambulatory peritoneal dialysis.
Andreoli SP; Dunn D; DeMyer W; Sherrard DJ; Bergstein JM
J Pediatr; 1985 Nov; 107(5):760-3. PubMed ID: 3932629
[No Abstract] [Full Text] [Related]
[Next] [New Search]
